SGMT Stock Analysis: Sagimet Biosciences Series | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 569m USD | 12M Return: 24.4% | US7867001049 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.8M
Warnings
Tailwinds
Seasonality 3.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sagimet Biosciences Inc. (SGMT) is a clinical-stage biopharmaceutical company headquartered in San Mateo, California, that focuses on developing fatty acid synthase (FASN) inhibitors to address diseases driven by dysfunctional metabolic and fibrotic pathways. Its lead drug candidate, Denifanstat, is an oral, once-daily selective FASN inhibitor being studied for metabolic dysfunction-associated steatohepatitis (MASH), acne, and select cancers, with a second FASN candidate (TVB-3567) in development for acne and additional oncology programs targeting solid tumors and glioblastoma. Founded in 2006 (originally as 3-V Biosciences, prior to its 2019 renaming) and listed on NASDAQ in July 2023, Sagimet operates in the biotechnology subsector, where clinical-stage companies typically rely on equity raises and partnerships rather than product revenue to fund research and development.
- Denifanstat Phase 3 MASH trial data readout approaches
- Rezdiffra competition from Madrigal pressures denifanstat market opportunity
- Cash burn risks dilutive secondary offering this year
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.16 > 0.02 and ΔFCF/TA 23.78 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.16 > 3% & CFO -41.3m > Net Income -47.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 45.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.1m) vs 12m ago 64.98% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.91 (Total Current Assets 244.0m - Total Current Liabilities 5.42m) / Total Assets 263.4m |
| B: -1.41 (Retained Earnings -371.0m / Total Assets 263.4m) |
| C: -0.26 (EBIT TTM -52.6m / Avg Total Assets 200.4m) |
| D: 35.21 (Book Value of Equity 256.2m / Total Liabilities 7.28m) |
| Altman-Z'' = 36.56 = AAA |
As of October 21, 2026, the stock is trading at USD 9.74 with a total of 2,169,395 shares traded. Over the past week, the price has changed by +22.06%, over one month by -9.81%, over three months by +36.03% and over the past year by +24.39%.
Current recommended Stop Loss: 9.00 (which is 7.6% or 1.2 ATR below the current price).
Sagimet Biosciences Series has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy SGMT.
- StrongBuy: 9
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 27.9 | 186.6% |
P/S = 52.4983
P/B = 2.5261
Revenue TTM = 0.0 USD
EBIT TTM = -52.6m USD
EBITDA TTM = -52.6m USD
Long Term Debt = 1.86m USD (estimated: total debt 1.94m - short term 84.0k)
Short Term Debt = 84.0k USD (from shortTermDebt, last quarter)
Debt = 1.94m USD (from shortLongTermDebtTotal, last quarter) (leases 1.94m already included)
Net Debt = -238.2m USD (calculated: Debt 1.94m - CCE 240.1m)
Enterprise Value = 330.5m USD (568.7m + Debt 1.94m - CCE 240.1m)
Interest Coverage Ratio = unknown (Ebit TTM -52.6m / Interest Expense TTM 0.0)
EV/FCF = -8.00x (Enterprise Value 330.5m / FCF TTM -41.3m)
FCF Yield = -12.50% (FCF TTM -41.3m / Enterprise Value 330.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 1.25 (Enterprise Value 330.5m / Total Assets 263.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.94m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -41.6m (EBIT -52.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 45.02 (Total Current Assets 244.0m / Total Current Liabilities 5.42m)
Debt / Equity = 0.01 (Debt 1.94m / totalStockholderEquity, last quarter 256.2m)
Debt / EBITDA = 4.53 (negative EBITDA) (Net Debt -238.2m / EBITDA -52.6m)
Debt / FCF = 5.76 (negative FCF - burning cash) (Net Debt -238.2m / FCF TTM -41.3m)
Total Stockholder Equity = 147.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.49% (Net Income -47.1m / Total Assets 263.4m)
RoE = -31.96% (Net Income TTM -47.1m / Total Stockholder Equity 147.3m)
RoCE = -35.28% (EBIT -52.6m / Capital Employed (Equity 147.3m + L.T.Debt 1.86m))
RoIC = -16.11% (negative operating profit) (NOPAT -41.6m / Invested Capital 258.1m)
WACC = 12.77% (E(568.7m)/V(570.6m) * Re(12.81%) + D(1.94m)/V(570.6m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.81% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 60.56 | Cagr: 30.78%
[DCF] Fair Price = unknown (Cash Flow -41.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.24 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.26 | Chg30d=-2.00% | Revisions=+0% | Analysts=11
EPS current Year (2026-12-31): EPS=-1.12 | Chg30d=+6.43% | Revisions=+57% | GrowthEPS=+29.1% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.30 | Chg30d=+5.62% | Revisions=+62% | GrowthEPS=-16.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +75% (up=9, down=0)